Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Novo Nordisk A/S buy tbackenh

Start price
€33.15
14.08.14 / 50%
Target price
€39.00
07.10.14
Performance (%)
9.86%
End price
€36.42
07.10.14
Summary
This prediction ended on 07.10.14 with a price of €36.42. With a performance of 9.86%, the BUY prediction by tbackenh for Novo Nordisk A/S closed with a slight gain. tbackenh has 50% into this prediction

Novo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.

Performance without dividends (%)
Name 1w 1m 1y 3y
Novo Nordisk A/S - - - -
iShares Core DAX® -2.926% -4.228% 9.878% 12.466%
iShares Nasdaq 100 4.462% 8.605% 33.063% 59.465%
iShares Nikkei 225® 0.306% 0.284% 3.871% 4.557%
iShares S&P 500 2.488% 4.773% 27.189% 50.113%

Comments by tbackenh for this prediction

In the thread Novo Nordisk A/S diskutieren
Prediction Buy
Perf. (%) 9.86%
Target price 39.000
Change
Ends at 07.10.14

Novo Nordisk

Novo Nordisk ist ein globales Unternehmen der Gesundheitsbranche und durch seine Innovationen seit über 90 Jahren führend in der Diabetesversorgung. Das Unternehmen hält außerdem führende Positionen in den Gebieten Blutgerinnung (Hämostase), Wachstumshormon- sowie Hormonersatztherapie. Mit Hauptsitz in Dänemark beschäftigt Novo Nordisk derzeit etwa 38.000 Menschen in 75 Ländern. In Deutschland – am Standort Mainz – sind derzeit rund 470 Mitarbeitern tätig. Die Novo Nordisk Produkte werden in 180 Ländern vertrieben. Für mich auch ein Profiteur des demographischen Wandels. Immer mehr gerade auch jüngere Menschen in den Industrieländern sind übergewichtet und damit wird der Markt für diesen Diabetesmarktführer immer größer... - traurig, aber leider wahr!

Prediction Buy
Perf. (%) 9.86%
Target price 39.000
Change
Ends at 07.10.14

(Stop Loss Kurs erreicht)